We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

This study has been terminated.
(Lack of primary outcome efficacy.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01059305
First Posted: January 29, 2010
Last Update Posted: April 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
OSI Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
  Purpose
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma. The safety of the drug will also be studied.

Condition Intervention Phase
Skin Cancer Drug: Erlotinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Overall Response [ Time Frame: 4 weeks ]
    Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = inevaluable. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): >30% decrease in sum of diameters of target lesions, reference baseline sum diameters. Progressive Disease (PD): >20% increase in sum of diameters of target lesions, reference smallest sum on study (this includes baseline sum if is smallest on study). In addition to relative increase of 20%, sum must absolute increase at least 5 mm. (Note: appearance of 1/> new lesions also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum diameters while on study. Not evaluable (NE): Inevaluable when no imaging/measurement done


Enrollment: 10
Study Start Date: February 2011
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Erlotinib
150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
Drug: Erlotinib
150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
Other Names:
  • OSI-774
  • Erlotinib Hydrochloride
  • Tarceva

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Within 12 weeks prior to study entry, patient must have histologically or cytologically confirmed cutaneous squamous cell carcinoma (CSCC) that is either locally advanced or recurrent, and no evidence of distant metastases. If the biopsy was collected outside of MD Anderson Cancer Center (MDACC), the MDACC Pathology Department must assess and confirm the SCC diagnosis.
  2. Patient is eligible with previous surgical intervention if they have residual or recurrent disease, it is greater than 6 weeks since surgery and they have fully recovered from the surgery.
  3. Patient must have measurable disease.
  4. Tumor must be at least 2 centimeters in size as measured by the treating physician(s) or PI, or have histological or cytological verification of muscle, bone, lymph node metastasis, or perineural involvement,.
  5. Surgical resection or radiation must be planned as part of the treatment strategy for the CSCC.
  6. At least 18 years of age.
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  8. Must have adequate organ and marrow function as follows:(a) leukocytes >/= 3,000/mm^3 (b) absolute neutrophil count >/= 1,500/mm^3 (c) platelets >/= 75,000/mm^3 (d) hemoglobin >/= 8g/dL (e) total bilirubin </= 2 X institutional upper limit of normal (ULN) (f) AST(SGOT)/ALT(SGPT) </= 2.5 X ULN if alkaline phosphatase is normal, or alkaline phosphatase </= 4 x ULN if transaminases are normal (g) Creatinine </= 2.0 x ULN or creatinine clearance >/= 60 mL/min/1.73 m^2
  9. Must be able to take intact tablets by mouth, or be able to take tablets dissolved in water by mouth or by a percutaneous gastrostomy tube.
  10. Patients - both males and females - with reproductive potential (includes women who are menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Birth control should continue for 4 weeks after discontinuation of erlotinib therapy. Women of childbearing potential must provide a negative pregnancy test (serum betaHCG) within within 72 hours prior to first receiving protocol therapy.
  11. Must have ability to understand and the willingness to sign a written Informed Consent Document (ICD). In the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an ICD in their language will be utilized and completed in accordance with the MDACC "Policy For Consenting Non-English Speaking Participants."
  12. Must be willing to receive their definitive local therapy, that is surgery and / or radiation therapy, at M. D. Anderson Cancer Center.
  13. Organ transplant patients are eligible as long as they do not have active signs of rejection and have adequate bone marrow function.

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or have child-bearing potential & are unwilling/unable to use an acceptable method of contraception for the entire study period & for at least 4 weeks after cessation of the study drugs. If the pregnancy test is positive, the patient must not receive erlotinib, & must not be enrolled on the study. Erlotinib is a signal transduction inhibitor agent w/ the potential for teratogenic or abortifacient effects.
  2. -continued from Exclusion #1- If the pregnancy test is positive, the patient must not receive erlotinib, and must not be enrolled on the study. Erlotinib is a signal transduction inhibitor agent with the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erlotinib, breastfeeding should be discontinued if the mother is treated with erlotinib.
  3. Patient with distant metastatic disease.
  4. Patient who has had previous radiotherapy to the site of the skin cancer being treated on this protocol.
  5. Patient currently receiving any other anticancer or investigational agents at time of study enrollment.
  6. Patient has received prior EGFR inhibitor therapy.
  7. Patient with a history of an invasive malignancy (other than the one treated in this study) or lymphoproliferative disorder within the past 5 years. Patients with a history of adequately treated non-melanoma skin cancer, ductal carcinoma in situ of the breast or carcinoma in situ of the cervix are allowed.
  8. Patient with history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib.
  9. Patient is unwilling or unable to discontinue prohibited concomitant therapies.
  10. In the opinion of the investigator, patient with any condition that is unstable or could jeopardize the safety of the patient or could limit compliance with the study's requirements. These include, but are not limited to, ongoing or active infection requiring parenteral antibiotics at time of study registration, psychiatric illness that would limit compliance with study requirements or symptomatic congestive heart failure (NYHA class II or greater), unstable angina pectoris or cardiac arrhythmia requiring maintenance medication.
  11. Patient with a history of pulmonary fibrosis (other than in a radiated field) or chronic liver disease.
  12. Patients with active gastrointestinal disease or a disorder that alters gastrointestinal motility or absorption; for example, a significant surgical resection of the stomach or small bowel, uncontrolled inflammatory bowel disease or uncontrolled chronic diarrhea.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01059305


Locations
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
OSI Pharmaceuticals
Investigators
Principal Investigator: Bonnie S. Glisson, MD, BS M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01059305     History of Changes
Other Study ID Numbers: 2009-0723
NCI-2011-00252 ( Registry Identifier: NCI CTRP )
First Submitted: January 28, 2010
First Posted: January 29, 2010
Results First Submitted: February 16, 2017
Results First Posted: April 4, 2017
Last Update Posted: April 4, 2017
Last Verified: February 2017

Keywords provided by M.D. Anderson Cancer Center:
Erlotinib
Erlotinib Hydrochloride
OSI-774
Tarceva
Squamous cell carcinoma of the skin
Aggressive cutaneous squamous cell carcinoma
CSCC
Local surgery
Radiation therapy
Epidermal growth factor receptor
EGFR
Small Molecule Tyrosine Kinase Inhibitor

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms, Squamous Cell
Carcinoma, Squamous Cell
Neoplasms by Site
Neoplasms
Skin Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action


To Top